These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37949359)

  • 1. Characterization of Immune Cell Populations of Cutaneous Neurofibromas in Neurofibromatosis 1.
    Kallionpää RA; Peltonen S; Le KM; Martikkala E; Jääskeläinen M; Fazeli E; Riihilä P; Haapaniemi P; Rokka A; Salmi M; Leivo I; Peltonen J
    Lab Invest; 2024 Jan; 104(1):100285. PubMed ID: 37949359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Clinicopathologic Study on the Role of Estrogen, Progesterone, and Their Classical and Nonclassical Receptors in Cutaneous Neurofibromas of Individuals With Neurofibromatosis 1.
    Rozza-de-Menezes RE; Almeida LM; Andrade-Losso RM; de Souza Vieira G; Siqueira OHK; Brum CI; Riccardi VM; Cunha KS
    Am J Clin Pathol; 2021 Apr; 155(5):738-747. PubMed ID: 33289020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mast Cells in Human Cutaneous Neurofibromas: Density, Subtypes, and Association with Clinical Features in Neurofibromatosis 1.
    Kallionpää RA; Ahramo K; Martikkala E; Fazeli E; Haapaniemi P; Rokka A; Leivo I; Harvima IT; Peltonen J; Peltonen S
    Dermatology; 2022; 238(2):329-339. PubMed ID: 34237737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ex Vivo Patient-Derived Explant Model for Neurofibromatosis Type 1-Related Cutaneous Neurofibromas.
    Grit JL; Turner L; Essenburg CJ; Gallik KL; Dischinger PS; Shurlow ND; Pate MJ; Graveel CR; Steensma MR
    J Invest Dermatol; 2024 Sep; 144(9):2052-2065.e8. PubMed ID: 38395106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous Neurofibromas and Quality of Life in Adults With Neurofibromatosis Type 1.
    Lin MJ; Yao H; Vera K; Patel E; Johnson M; Caroline P; Ramos J; Mehta J; Hu X; Blakeley JO; Romo CG; Sarin KY
    JAMA Dermatol; 2024 Oct; 160(10):1091-1098. PubMed ID: 39196570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.
    Church C; Fay CX; Kriukov E; Liu H; Cannon A; Baldwin LA; Crossman DK; Korf B; Wallace MR; Gross AM; Widemann BC; Kesterson RA; Baranov P; Wallis D
    Acta Neuropathol Commun; 2024 Jun; 12(1):102. PubMed ID: 38907342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.
    Nguyen HTL; Kohl E; Bade J; Eng SE; Tosevska A; Al Shihabi A; Tebon PJ; Hong JJ; Dry S; Boutros PC; Panossian A; Gosline SJC; Soragni A
    Cell Rep Methods; 2024 May; 4(5):100772. PubMed ID: 38744290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous neurofibroma cells with active YAP promotes proliferation of macrophages resulting in increased accumulation of macrophages by modulating CCL5 and TGF‑β1.
    Jia J; Zhang H; He L; Zhang H; Shu M
    Oncol Rep; 2020 Apr; 43(4):1319-1330. PubMed ID: 32323813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Econazole selectively induces cell death in NF1-homozygous mutant tumor cells.
    Lakes YB; Moye SL; Mo J; Tegtmeyer M; Nehme R; Charlton M; Salinas G; McKay RM; Eggan K; Le LQ
    Cell Rep Med; 2023 Dec; 4(12):101309. PubMed ID: 38086379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Target Product Profile for Cutaneous Neurofibromas: Clinical Trials to Prevent, Arrest, or Regress Cutaneous Neurofibromas.
    Ly I; Romo CG; Gottesman S; Kelly KM; Kornacki D; York Z; Lee SY; Rhodes SD; Staedtke V; Steensma MR; Blakeley JO; Wolkenstein P
    J Invest Dermatol; 2023 Aug; 143(8):1388-1396. PubMed ID: 37294242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular Origin, Tumor Progression, and Pathogenic Mechanisms of Cutaneous Neurofibromas Revealed by Mice with
    Radomska KJ; Coulpier F; Gresset A; Schmitt A; Debbiche A; Lemoine S; Wolkenstein P; Vallat JM; Charnay P; Topilko P
    Cancer Discov; 2019 Jan; 9(1):130-147. PubMed ID: 30348676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and Emerging Imaging Techniques for Neurofibromatosis Type 1-Associated Cutaneous Neurofibromas.
    Li Y; Blakeley JO; Ly I; Berman Y; Lau J; Wolkenstein P; Bergqvist C; Jia W; Milner TE; Katta N; Durkin AJ; Kennedy GT; Rowland R; Romo CG; Fleming J; Kelly KM
    J Invest Dermatol; 2023 Aug; 143(8):1397-1405. PubMed ID: 37330718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAS Signaling Gone Awry in the Skin: The Complex Role of RAS in Cutaneous Neurofibroma Pathogenesis, Emerging Biological Insights.
    Rhodes SD; McCormick F; Cagan RL; Bakker A; Staedtke V; Ly I; Steensma MR; Lee SY; Romo CG; Blakeley JO; Sarin KY
    J Invest Dermatol; 2023 Aug; 143(8):1358-1368. PubMed ID: 37245145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical delivery of mitogen-activated protein kinase inhibitor binimetinib prevents the development of cutaneous neurofibromas in neurofibromatosis type 1 mutant mice.
    Coulpier F; Pulh P; Oubrou L; Naudet J; Fertitta L; Gregoire JM; Bocquet A; Schmitt AM; Wolkenstein P; Radomska KJ; Topilko P
    Transl Res; 2023 Nov; 261():16-27. PubMed ID: 37331503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.
    Mazuelas H; Magallón-Lorenz M; Uriarte-Arrazola I; Negro A; Rosas I; Blanco I; Castellanos E; Lázaro C; Gel B; Carrió M; Serra E
    JCI Insight; 2024 Jan; 9(3):. PubMed ID: 38175707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct Transcriptional Profiles in the Different Phenotypes of Neurofibroma from the Same Subject with Neurofibromatosis 1.
    Wang WN; Koguchi-Yoshioka H; Nimura K; Watanabe R; Tanemura A; Fujimoto M; Wataya-Kaneda M
    J Invest Dermatol; 2024 Jan; 144(1):133-141.e4. PubMed ID: 37301319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Existing and Developing Preclinical Models for Neurofibromatosis Type 1-Related Cutaneous Neurofibromas.
    Staedtke V; Topilko P; Le LQ; Grimes K; Largaespada DA; Cagan RL; Steensma MR; Stemmer-Rachamimov A; Blakeley JO; Rhodes SD; Ly I; Romo CG; Lee SY; Serra E
    J Invest Dermatol; 2023 Aug; 143(8):1378-1387. PubMed ID: 37330719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular wall cells contribute to tumourigenesis in cutaneous neurofibromas of patients with neurofibromatosis type 1. A comparative histological, ultrastructural and immunohistochemical study.
    Friedrich RE; Holstein AF; Middendorff R; Davidoff MS
    Anticancer Res; 2012 May; 32(5):2139-58. PubMed ID: 22593502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous neurofibromas: Current clinical and pathologic issues.
    Ortonne N; Wolkenstein P; Blakeley JO; Korf B; Plotkin SR; Riccardi VM; Miller DC; Huson S; Peltonen J; Rosenberg A; Carroll SL; Verma SK; Mautner V; Upadhyaya M; Stemmer-Rachamimov A
    Neurology; 2018 Jul; 91(2 Suppl 1):S5-S13. PubMed ID: 29987130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.
    Grit JL; Johnson BK; Dischinger PS; J Essenburg C; Adams M; Campbell S; Pollard K; Pratilas CA; Triche TJ; Graveel CR; Steensma MR
    Epigenetics Chromatin; 2021 Jan; 14(1):7. PubMed ID: 33436083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.